Palovarotene MOA

Share this article with:

Fibrodysplasia ossificans progressiva, or FOP, is an extremely rare and debilitating disorder, in which bone tissue gradually replaces soft tissue throughout the body, extending the skeleton and “freezing” patients into position. FOP is an autosomal dominant disorder, and is believed to be caused by a mutation in the ACVR1 gene, which results in constitutively active BMP signaling. Clementia Pharmaceuticals is investigating Palovarotene as a RAR-gamma agonist capable of inhibiting BMP signaling, which may prevent heterotopic ossification and slow the progression of this devastating disease.

Share It:
Contact XVIVO


Palovarotene MOA

The best things about working with XVIVO is probably the final product, that is never disappointing but, on the contrary, always beyond expectation. Our clients are happy and so are we. The second best thing is a very good production and revision process thru the web with a reliable schedule. It’s good not to be anxious because you know things will be done in due time (and well done).

Jean-Pascal Huvé, ScienceProd (Paris, France)